ClinicaliQ Trial Snapshot
- Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight — Recruiting • Phase III • Diabetes / Metabolic • NCT07353931.
- A trial testing whether eloralintide injection reduces knee osteoarthritis pain in overweight or obese adults over 75 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening. Conditions: Osteoarthritis, Overweight or Obesity Interventions: Eloralintide, Placebo Lead Sponsor: Eli Lilly and Company Planned Enrollment: 900 participants